Can You Stay on 2.5mg Tirzepatide Longer Than Four Weeks?

Step 1: Why 2.5mg exists in the schedule at all

Tirzepatide's licensed starting dose is 2.5mg, injected once weekly for the first four weeks. The Mounjaro prescribing information is clear that this dose is not intended to produce meaningful weight reduction. Its purpose is tolerability. Nausea, indigestion and loose stools are the most commonly reported early side effects, and beginning low gives the gastrointestinal system time to adapt before the dose that actually influences appetite and weight kicks in.

Think of the first pen as a settling-in period. You keep it in the fridge door next to everything else, you inject on the same day each week, and the main thing you are doing is building a foundation for the doses that follow. Most people find the GI discomfort manageable at 2.5mg; for a smaller group it is still significant enough to suggest the titration should slow down.

According to the NHS tirzepatide medicines page, the standard schedule escalates in 2.5mg increments roughly every four weeks, with the prescriber guiding that pace. If you are wondering whether staying on 2.5mg of Mounjaro is a realistic option for you, the answer depends on your clinical picture, not a fixed timeline. A prescriber who knows your history can read the signs that you need a longer run at the current dose, and that is a legitimate, supported clinical decision, not an exception to the rules.

Step 2: When extending 2.5mg is clinically justified

There is no universal rule that forces a dose increase at exactly week five. If you are experiencing persistent nausea, significant vomiting or other GI symptoms that have not settled by the end of your first four weeks, your prescriber may recommend staying at 2.5mg for a further four weeks before moving to 5mg. This is a recognised feature of real-world titration and is consistent with how the medicine is used in clinical practice.

What is not appropriate is staying at 2.5mg indefinitely without clinical review. At that dose, the evidence for meaningful weight loss is not established; the move to 5mg is where the medicine starts to show its intended effect for most people. Staying too long at the starter dose because you feel comfortable (rather than because side effects require it) means you are likely not getting the benefit you started treatment for.

At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is approved. If your symptoms have settled, they will talk through the case for moving up. If they have not, they will discuss whether continuing at 2.5mg makes sense for you specifically. A prescriber reads your clinical picture; a dose calendar does not.

Step 3: What happens if you never move beyond 2.5mg

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks. Those figures come from participants who titrated through the schedule, not from those who stayed at 2.5mg. There is no trial evidence that 2.5mg as a long-term maintenance dose produces clinically meaningful weight loss, that is simply not what it was designed or tested for.

If side effects are so persistent that reaching even 5mg feels impossible, that is important clinical information. It might point to a need for a slower titration, a temporary pause, or a frank conversation about whether tirzepatide is the right medicine for you. Those are all conversations for a prescriber. Our clinical team hears questions like this regularly and there is no pressure to rush through a schedule that your body is resisting.

For context on how the dose progression compares at the next step, the question of staying on 5mg follows a similar logic, again, a clinical decision made individually, not a one-size policy.

Getting a prescriber's view without a GP referral

Tirzepatide (Mounjaro) is a prescription-only medicine. Whether you are starting treatment, considering whether to hold your current dose, or thinking about transferring from another provider, a clinical assessment is the required first step. There is no shortcut to a legitimate prescription, and you should be cautious about any source that offers these medicines without one, the MHRA has warned publicly about counterfeit pens sold through unofficial channels, some of which have caused serious harm.

The private route through a regulated pharmacy like nume removes the waiting-list pressure of NHS access without removing the clinical layer. You can read more about weight-loss treatment options or look at the cost context for Mounjaro if that is part of what you are weighing up. The right question to start with, though, is whether the treatment is clinically suitable for you, and our prescribers are there to answer that.

If you have questions outside of a formal consultation, the FAQs page covers a range of common clinical queries, and the support team is available seven days a week.